



897351  
1-14



*[Handwritten signature]*

Ligand Component =  
fCmGmGrArAtUfCmAmGfUmGmAmAtUmGfCfUfUmAtUmAtCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)

FIG. 1A




Ligand Component =  
fCmGmGrArAtUfCmAmGfUmGmAmAtUmGfCfUfUmAtUmAtCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)

FIG. 1B


08897351.072197

897351  
2-14



Ligand Component =  
tCmGmGrArAtUfCmAmGfUmGmAmaAtUmGfCfUfUmAtUmAtCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)


FIG. 1C



Ligand Component =  
tCmGmGrArAtUfCmAmGfUmGmAmaAtUmGfCfUfUmAtUmAtCmAfUfCfCmG-3'3'-dT  
(VEGF ligand)

FIG. 1D

897351  
3-14



NX31838 20Kb PEG


Ligand Component =

fCmGmGrArAtfCmAmGfUmGmAmAtUmGfCfUfUmAtfCmAtfUfCfCmG-3'3'-dT

(VEGF ligand)


FIG. 1E

897351  
4-14




C-5 Amino linker

FIG. 1F



Glycerol bisphosphate

FIG. 1G



18 atom spacer

FIG. 1H

06897351.072197

897351  
5-14




FIG. 11

897351-0219

897351  
6-14

**VEGF Nucleic Acid Ligand  
NX31838 Conjugated to  
PEG20K and PEG40K:  
Plasma Pharmacokinetics in  
Sprague Dawley Rats  
(dose 1 mg/kg)**




FIGURE 2

08097351.02497  
26T220" T5E26880

897351  
17-14

**VEGF Nucleic Acid Ligand  
NX31838 Conjugated  
to PL Lipid;  
Plasma Pharmacokinetics  
in Sprague Dawley Rats  
(dose 1 mg/kg)**





FIGURE 3

261220 T526880

897351  
8-14



**FIG. 4A**



897351  
9-14




FIG. 4B

897351  
10-14




FIG. 4C

897351  
11-14




FIG. 5A

451240 TEE 45830

897351  
12-14




FIG. 5B

**SECRET**



897351  
14-14

Figure 6: Pharmacokinetic Study of  
Intravitreal Administration  
of NX31838-40mPEG in Rabbits

